CHMP rejects Elevidys in latest setback for Sarepta

Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy, Elevidys, received a negative opinion from the European Medicines Agency's (EMA) CHMP, citing the pivotal EMBARK trial's failure to meet its primary endpoint for movement abilities despite observed dystrophin production. This European regulatory setback, which comes despite Roche holding ex-US rights and planning to engage the EMA, compounds recent challenges for Sarepta, including a US FDA-requested pause on Elevidys shipments following reported patient deaths linked to its AAV gene therapy platform.

Analysis

Sarepta Therapeutics faces a significant dual setback for its gene therapy franchise, headlined by a negative opinion from the European Medicines Agency's (EMA) CHMP for its Duchenne muscular dystrophy (DMD) therapy, Elevidys. The rejection was based on the pivotal EMBARK trial's failure to meet its primary endpoint of improving movement abilities, a critical efficacy measure that the committee found was not sufficiently linked to the observed production of dystrophin protein. While commercialization partner Roche, which holds ex-US rights, intends to pursue further dialogue with the EMA, highlighting that secondary functional endpoints were met, the immediate path to European market access is blocked. This regulatory failure is compounded by severe safety concerns in the US, where Sarepta has paused Elevidys shipments at the FDA's request following a third patient death in its gene therapy programs. The issue points to a potential platform-level risk, as the death occurred in a trial for a separate drug, SRP-9004, which utilizes the same AAVrh74 serotype as Elevidys, intensifying scrutiny on the underlying technology.

Key Decisions for Investors

• Investors should recognize the heightened risk profile for Sarepta, as the European regulatory failure for Elevidys on efficacy grounds, combined with the US shipment halt due to platform-wide safety concerns, creates substantial uncertainty for a key asset.
• Monitor for any updates from Roche's planned engagement with the EMA, as this represents the only potential path forward in Europe, and track the outcome of the FDA's review of the AAVrh74 platform's safety profile, which is critical for lifting the US shipment pause.
• Re-evaluate the development risk across Sarepta's entire gene therapy pipeline, as the safety issues tied to the AAVrh74 serotype may have negative implications for other candidates using the same delivery vector, potentially impacting future clinical trials and regulatory pathways.